ERBB2 and breast cancer: BC treatment guidelines indicate that a Trastuzumab-based regimen is the recommended first-line approach for patients with HER2-positive recurrent metastatic BC who have not previously undergone adjuvant therapy with Trastuzumab (31, 32).